Clinical TrialJun 25, 2026, 08:31 AM
PRF Technologies PRF-110 Preclinical Study Shows Favorable PK Profile
AI Summary
PRF Technologies Ltd. announced expanded preclinical study results for its lead product candidate, PRF-110, comparing it to ZYNRELEF®. The study showed PRF-110 had comparable analgesic efficacy to the benchmark, along with a favorable pharmacokinetic profile characterized by slower absorption and enhanced local tissue retention. These findings reinforce confidence in PRF-110 as a differentiated, long-acting solution for post-operative pain management, aiming to reduce opioid use.
Key Highlights
- PRF-110 demonstrated comparable analgesic efficacy to ZYNRELEF in a porcine post-operative pain model.
- PRF-110 exhibited a slower absorption rate compared to ZYNRELEF, suggesting a more gradual release.
- PRF-110 showed increased retention in local tissue and higher local tissue exposure (Cmax).
- Both PRF-110 and ZYNRELEF demonstrated sustained systemic and local drug levels.
- PRF-110 is an oil-based, viscous, clear extended-release formulation of ropivacaine.
Price Impact
More from PRFX